



Attorney Docket No. RDYN:M.13/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	BERGE ET AL.	}	EXAMINER:
SERIAL NO.:	10/729,416		ART UNIT: 1625
FILED:	DECEMBER 5, 2003		CONFIRMATION NO.: 8376
TITLE:	2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(c). This Statement is filed after three months from the filing date of the national application, after three months from the date of entry into national stage under 37 CFR § 1.491, after the mailing of a first Office Action on the merits, or after the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114, but before the mailing date of any of:

- (a) a final action under 37 CFR § 1.113;
- (b) a notice of allowance under 37 CFR § 1.311; or
- (c) an action that otherwise closes prosecution in the application.

This Statement is accompanied by a check for \$180 in accordance with 37 CFR §§1.97(c) and 1.17(p). The undersigned hereby authorizes the charging of any deficiency of fees submitted herewith to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an

10/21/2004 FFANAI2 00000026 10729416

01 FC:1806

180.00 OP

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 15, 2004.


Signature:
Name:

Tasha L. Pierce

admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: October 15, 2004



Darla G. Yoerg, #48,053

Swanson & Bratschun, L.L.C.

1745 Shea Center Drive, Suite 330

Highlands Ranch, Colorado 80129


Telephone: (303) 268-0066

Facsimile: (303) 268-0065

cc: V. Appleby

S:\CLIENTFOLDERS\REPLIDYNE\MRS13\M13US\IDS.DOC

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 1	ATTY. DOCKET NO. RDYN.M.13/US	SERIAL NO. 10729416
	APPLICANT BERGE et al.	
	FILING DATE 12/5/03	GROUP 1614



U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AJ	EP 0 785 268	7/23/97	EPO			
	AK	WO 00/71522	11/30/00	PCT			
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AQ	Van der Wenden et al. (1995) European J. Pharma. 290:189-199
	AR	Peyman et al. (2000) Angew. Chem. Int. Ed. 39(16):2874-2877
	AS	Jarvest et al. (2002) J. Med. Chem. 45(10):1959-1962
	AT	Iwao et al. (1992) Heterocycles 34(5):1031-1038
	AU	Barlin et al. (1982) Aust. J. Chem. 35:2299-2306
	AV	Fleischmann et al. (1995) Science 269:496-519
	AW	Lespagnol et al. (1968) Ann. Pharm. Fr. 26(3):207-214 (and abstract in English)
	AX	
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		